loading page

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses. EAACI task force on eicosanoids consensus report in times of COVID-19
  • +14
  • Milena Sokolowska,
  • G Enrico Rovati,
  • Zuzana Diamant,
  • Eva Untersmayr,
  • Jürgen Schwarze,
  • Lukasik Z.,
  • Florentina Sava,
  • Alba Angelina,
  • Oscar Palomares,
  • Cezmi Akdis,
  • Liam O'Mahony,
  • Milos Jesenak,
  • Oliver Pfaar,
  • María José Torres,
  • Marek Sanak,
  • Sven-Erik Dahlén,
  • Grzegorz Woszczek
Milena Sokolowska
Universitat Zurich Schweizerisches Institut fur Allergie- und Asthmaforschung

Corresponding Author:milena.sokolowska@siaf.uzh.ch

Author Profile
G Enrico Rovati
University of Milan Graduate School in Social and Political Sciences
Author Profile
Zuzana Diamant
Lunds Universitet Lungmedicin och Allergologi
Author Profile
Eva Untersmayr
Medizinische Universitat Wien Zentrum fur Pathophysiologie Infektiologie und Immunologie
Author Profile
Jürgen Schwarze
The University of Edinburgh Edinburgh Medical School
Author Profile
Lukasik Z.
Universitat Zurich Schweizerisches Institut fur Allergie- und Asthmaforschung
Author Profile
Florentina Sava
University College London Great Ormond Street Institute of Child Health Library
Author Profile
Alba Angelina
Complutense University of Madrid Bibliotecas
Author Profile
Oscar Palomares
Complutense University of Madrid Bibliotecas
Author Profile
Cezmi Akdis
Universitat Zurich Schweizerisches Institut fur Allergie- und Asthmaforschung
Author Profile
Liam O'Mahony
University College Cork
Author Profile
Milos Jesenak
Department of Pulmonology and Phthisiology Department of Allergology and Clinical Immunology Department of Pediatrics Jessenius Faculty of Medicine in Martin Comenius University in Bratislava University Teaching Hospital in Martin Slovakia
Author Profile
Oliver Pfaar
Philipps Universitat Marburg Kunstgeschichtliches Institut
Author Profile
María José Torres
Universidad de Malaga
Author Profile
Marek Sanak
Uniwersytet Jagiellonski w Krakowie Wydzial Lekarski
Author Profile
Sven-Erik Dahlén
Karolinska Institutet Institutet for miljomedicin
Author Profile
Grzegorz Woszczek
MRC and Asthma UK Centre in Allergic Mechanisms of Asthma
Author Profile

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarises currently available knowledge, novel discoveries and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarise the major knowledge gaps and unmet needs in current eicosanoid research.
24 Nov 2021Submitted to Allergy
24 Nov 2021Submission Checks Completed
24 Nov 2021Assigned to Editor
26 Nov 2021Reviewer(s) Assigned
09 Dec 2021Review(s) Completed, Editorial Evaluation Pending
21 Dec 2021Editorial Decision: Revise Minor
21 Jan 20221st Revision Received
26 Jan 2022Submission Checks Completed
26 Jan 2022Assigned to Editor
26 Jan 2022Reviewer(s) Assigned
27 Jan 2022Review(s) Completed, Editorial Evaluation Pending
11 Feb 2022Editorial Decision: Accept
Aug 2022Published in Allergy volume 77 issue 8 on pages 2337-2354. 10.1111/all.15258